Literature DB >> 9184638

Detection of CSF-specific oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocal leukoencephalopathy.

C J Sindic1, C Trebst, M P Van Antwerpen, S Frye, W Enzensberger, G Hunsmann, W Lüke, T Weber.   

Abstract

The intrathecal synthesis of antibodies against recombinant VP1, the major structural protein of JC virus (JCV), was studied in 18 patients with progressive multifocal leukoencephalopathy (PML) and in 31 patients with various neurological disorders. Two methods were used, the calculation of an antibody specific index (ASI) on one hand and an antigen-driven immunoblotting for the detection of oligoclonal antibodies on the other. Most PML patients displayed an elevated (> 1.5) ASI (78%) and anti-VP1 oligoclonal antibodies restricted to the cerebrospinal fluid (55%). Only two other patients (one case each of multiple sclerosis and of neuroborreliosis) also showed an intrathecal synthesis of anti-VP1 oligoclonal antibodies, likely as a result of a 'polyspecific' reaction within the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184638     DOI: 10.1016/s0165-5728(97)00037-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

Review 1.  Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy.

Authors:  C T Yiannoutsos; A De Luca
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 2.  Viruses and multiple sclerosis.

Authors:  Gregory P Owens; Don Gilden; Mark P Burgoon; Xiaoli Yu; Jeffrey L Bennett
Journal:  Neuroscientist       Date:  2011-12       Impact factor: 7.519

Review 3.  Immunology of progressive multifocal leukoencephalopathy.

Authors:  Ivan Jelcic; Ilijas Jelcic; Wolfgang Faigle; Mireia Sospedra; Roland Martin
Journal:  J Neurovirol       Date:  2015-03-05       Impact factor: 2.643

Review 4.  Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency.

Authors:  S A Misbah
Journal:  Clin Exp Immunol       Date:  2017-03-27       Impact factor: 4.330

Review 5.  Progressive multifocal leukoencephalopathy and other forms of JC virus disease.

Authors:  Bruce J Brew; Nicholas W S Davies; Paola Cinque; David B Clifford; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2010-12       Impact factor: 42.937

Review 6.  [Progressive multifocal leukoencephalopathy].

Authors:  J C Wasmuth; A Wasmuth-Pietzuch; U Spengler; J K Rockstroh
Journal:  Med Klin (Munich)       Date:  1999-05-15

Review 7.  Immune response in progressive multifocal leukoencephalopathy: an overview.

Authors:  T Weber; F Weber; H Petry; W Lüke
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

8.  Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Clemens Warnke; Gloria von Geldern; Philipp Markwerth; Thomas Dehmel; Robert Hoepner; Ralf Gold; Michael Pawlita; Tania Kümpfel; Mathias Mäurer; Martin Stangel; Florian Wegner; Reinhard Hohlfeld; Vera Straeten; Volker Limmroth; Thomas Weber; Derik Hermsen; Christoph Kleinschnitz; Hans-Peter Hartung; Mike P Wattjes; Anders Svenningson; Eugene Major; Tomas Olsson; Bernd C Kieseier; Ortwin Adams
Journal:  Ann Neurol       Date:  2014-05-08       Impact factor: 10.422

Review 9.  B cells and progressive multifocal leukoencephalopathy: search for the missing link.

Authors:  Deniz Durali; Marie-Ghislaine de Goër de Herve; Jacques Gasnault; Yassine Taoufik
Journal:  Front Immunol       Date:  2015-05-19       Impact factor: 7.561

10.  Rapid cognitive decline in a patient with chronic lymphocytic leukaemia: a case report.

Authors:  James Forryan; Jun Yong
Journal:  J Med Case Rep       Date:  2020-03-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.